These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 8092158)

  • 1. Cost-effectiveness, not cost containment.
    Zbrozek AS
    Am J Hosp Pharm; 1994 Jun; 51(12):1569-71. PubMed ID: 8092158
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacoeconomic analyses: whose perspective counts and costs the most?
    Rubenstein EB; Elting LS
    Am J Hosp Pharm; 1994 Jun; 51(12):1564-9. PubMed ID: 8092157
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting.
    Zbrozek AS; Cantor SB; Cardenas MP; Hill DP
    Am J Hosp Pharm; 1994 Jun; 51(12):1555-63. PubMed ID: 8092156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.
    Lachaine J; Laurier C; Langleben A; Vaillant L
    Crit Rev Oncol Hematol; 1999 Nov; 32(2):105-12. PubMed ID: 10612010
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
    Kwong WJ; Parasuraman TV
    Pharm Pract Manag Q; 1999 Apr; 19(1):28-41. PubMed ID: 10351607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ondansetron: a specific serotonin antagonist for the prevention of chemotherapy-induced vomiting.
    Kris MG
    Important Adv Oncol; 1994; ():165-77. PubMed ID: 8206488
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
    Manusirivithaya S; Chareoniam V; Isariyodom P; Sungsab D
    J Med Assoc Thai; 2001 Jul; 84(7):966-72. PubMed ID: 11759977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.
    Lordick F; Ehlken B; Ihbe-Heffinger A; Berger K; Krobot KJ; Pellissier J; Davies G; Deuson R
    Eur J Cancer; 2007 Jan; 43(2):299-307. PubMed ID: 17134890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
    Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A
    J BUON; 2007; 12(2):245-52. PubMed ID: 17600880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [On what indication should serotonin antagonists be used? A retrospective study of the use of ondansetron at an oncologic unit].
    Norum J
    Tidsskr Nor Laegeforen; 1993 Aug; 113(18):2235-8. PubMed ID: 8362385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous infusion metoclopramide: clinical trials, pharmacokinetic considerations and cost-effectiveness.
    Parashos PJ; Dugan WM; Fry MW
    Prog Clin Biol Res; 1987; 248():303-11. PubMed ID: 3118389
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
    Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
    Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
    Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery.
    Krobbuaban B; Pitakpol S; Diregpoke S
    J Med Assoc Thai; 2008 May; 91(5):669-74. PubMed ID: 18672630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-examination of clinical aspects of pharmacoeconomic analysis.
    Rubenstein EB; Elting LS
    Am J Hosp Pharm; 1994 Dec; 51(23):2970-3. PubMed ID: 7879813
    [No Abstract]   [Full Text] [Related]  

  • 16. [Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin].
    Harousseau JL
    Bull Cancer; 1996 Jan; 83(1):71-76. PubMed ID: 8672859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of postoperative nausea and vomiting with ondansetron in patients administered anti-neoplastic agents].
    Morimoto Y; Nakamura M; Tamura T; Kunii T; Shimizu K; Miyauchi Y
    Masui; 1996 Sep; 45(9):1096-9. PubMed ID: 8905945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nurses' perceptions of antiemetic effectiveness.
    Rhodes VA; McDaniel RW; Simms SG; Johnson M
    Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between steady state metoclopramide levels and control of emesis during treatment with cis-platinum.
    Kerr DJ; Graham J; Blackie RG; McGovern E; Kelman AW; Cunningham D; Kaye SB
    Br J Clin Pharmacol; 1985 Oct; 20(4):426-7. PubMed ID: 4074612
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: 'Cost-effectiveness of 5-hydroxytryptamin3 receptor antagonists: a retrospective comparison of ondansetron and granisetron'.
    Thwaites R; Parasuraman TV; Paska W
    Anticancer Drugs; 1996 Jan; 7(1):127-30. PubMed ID: 8742110
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.